Impact of rotavirus vaccination
In Europe, routine rotavirus vaccination of infants at the national level has been introduced with one or two vaccine brands in Finland, Austria, Luxembourg and Belgium within well-baby clinics or administered by general practitioners and paediatricians. When introducing a new vaccine, it is crucial to conduct studies evaluating the vaccination’s impact and effectiveness in order to decide on recommendations for its future use. To this end, ECDC has produced three generic protocols: a protocol for developing cohort studies to assess the effectiveness of the rotavirus vaccination in EU Members States; a protocol proposing prospective case control study designs to estimate rotavirus vaccine effectiveness; and a protocol for developing studies to assess the impact of rotavirus vaccination EU Member States.
Risk assessment guidelines for infectious diseases transmitted on aircraft (RAGIDA) - Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
22 Jan 2020 - The Middle East respiratory syndrome coronavirus (MERS-CoV) was first discovered in 2012 in a patient who died from severe respiratory disease. Since then, and as of 16 January 2020, 2 521 cases have been reported worldwide, including 919 deaths (crude case fatality 36%). Most cases have been reported from the Arabian Peninsula (and around 84% specifically from Saudi Arabia), and all cases elsewhere had a travel history to the Arabian Peninsula or were a contact of someone who had a travel history to the region.
Influenza communication guide: How to increase influenza vaccination uptake and promote preventive measures to limit its spread
21 Nov 2019 - The influenza vaccination communication guide provide advice, guidance and campaign materials to support national influenza vaccination campaigns with the purpose of increasing the influenza vaccination uptake in the EU Member States.
Options for national testing and surveillance for hepatitis E virus in the EU/EEA - Operational guidance
5 Sep 2019 - This operational guidance, developed by ECDC in collaboration with its hepatitis E virus (HEV) expert group, offers options on the implementation or adjustment of HEV surveillance at a national level.